← FDA DRUG APPROVALS
FDA ANDA · ANDA076348
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Sponsor: ANI PHARMS
APPLICATION
ANDA076348
TYPE
ANDA
ORIGINAL APPROVAL
2004-02-11
LATEST ACTION
2009-03-27
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
BENAZEPRIL HYDROCHLORIDE 20MG, HYDROCHLOROTHIAZIDE 12.5MG · TABLET · ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
BENAZEPRIL HYDROCHLORIDE 5MG, HYDROCHLOROTHIAZIDE 6.25MG · TABLET · ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
BENAZEPRIL HYDROCHLORIDE 20MG, HYDROCHLOROTHIAZIDE 25MG · TABLET · ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
BENAZEPRIL HYDROCHLORIDE 10MG, HYDROCHLOROTHIAZIDE 12.5MG · TABLET · ORAL
Approval history
2009-03-27Labeling · Supplement 11AP
2008-08-22Labeling · Supplement 9AP
2007-09-25Labeling · Supplement 7AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.